NASDAQ · ICCCHealthcareDiagnostics

Immucell news

$9.97+0.86%
Close Sep 29, 2026 · split-adjusted
Articles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0

About Immucell

ImmuCell Stock Falls 8.8% Despite Y/Y Earnings & Sales Growth in Q2
Zacks Investment ResearchAug 27, 10:10 AM ETNeutral

Mixed results with positive revenue growth (11.5% quarterly, 20.9% YTD) and strong domestic sales momentum (27.7%), but offset by significant gross margin contraction (43.7% to 33.9%), international sales decline (-38.9%), and manufacturing cost pressures. Stock declined 8.8% post-earnings. Positive outlook includes capacity expansion and market share gains, but execution risks remain around contamination, competition, and yield improvements.

Also mentions ICCC

Articles that tag ICCC but are mainly about other companies.

None recently.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology